サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726267

閉経後骨粗鬆症治療の世界市場：市場規模・シェア・動向分析 (薬剤クラス別・種類別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Postmenopausal Osteoporosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
閉経後骨粗鬆症治療の世界市場：市場規模・シェア・動向分析 (薬剤クラス別・種類別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月14日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

閉経後骨粗鬆症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の閉経後骨粗鬆症治療の市場規模は2030年までに137億米ドルに達し、2025年から2030年にかけてCAGR 4.6％で拡大すると予測されています。

高齢者人口の増加とライフスタイルの変化により、市場は大きく成長しています。高齢者人口は影響を受けやすいため、その人口増加が市場拡大の大きな原動力になると予測されています。例えば、世界保健機関（WHO）の2021年10月の報告書によると、60歳以上の高齢者数は2020年の10億人から2030年には14億人、2050年には21億人に増加すると予測されています。その結果、高齢者の閉経後骨粗鬆症治療需要の増加により、市場は予測期間中に拡大すると予想されます。

また、運動不足、過度の飲酒、喫煙、長時間労働、不健康な食事パターンなどの生活習慣の悪化は、更年期に影響を及ぼし、世界中の多くの女性の骨粗鬆症リスクを高めます。さらに、年齢、喫煙、飲酒、ゴナドトロピン、甲状腺ホルモンの過剰使用、細胞毒性剤のような病気に対処するための薬剤の使用は、閉経後の女性の骨密度の低下や症状の開発につながる危険因子のいくつかです。そのため、市場成長の原動力となります。国際更年期学会（IMS）の統計によると、2021年には2億人以上の女性が骨粗鬆症に罹患し、50歳以上の女性の3人に1人が骨粗鬆症による骨折を起こすと予測されています。前述の要因から、調査対象市場は予測期間中に拡大すると予想されます。

しかし、予測期間中は、この病気に対する認知度の低さが業界の成長を阻害すると予想されます。予測期間中、業界参加者や研究機関による投資の結果、研究開発への取り組みが大幅に増加する可能性が高いです。例えば、clinicaltrial.govに掲載された情報によると、2021年6月現在、米国では骨粗鬆症治療薬の第III相および第IV相臨床試験が約25件進行中です。例えば、イーライリリー・アンド・カンパニーは、閉経後骨粗鬆症を治療するために、ヒト化IgG4モノクローナル抗体であるブロソズマブを創製しています。これはSOSTタンパク質の阻害剤であり、現在第II相臨床試験中です。

閉経後骨粗鬆症治療市場レポート・ハイライト

  • ブランド骨粗鬆症治療薬が市場を独占し、2024年には54.0%のシェアを占めています。これらの医薬品は、有効性が実証されていること、規制当局の承認が得られていること、市場での存在感が強いことなどから、広く使用されています。
  • 2024年には小売薬局が市場を独占しました。高齢者人口の増加と骨粗鬆症の有病率の増加が、この流通チャネルを通じた医薬品需要を促進する主な要因となっています。
  • 北米は、主要市場参入企業のプレゼンスが高く、研究開発費の増加や連邦政府の支援もあることから、2024年に最大のシェアを占めました。
  • アジア太平洋は、対象疾患の有病率の上昇、高齢化人口の増加、閉経後骨粗鬆症治療薬の採用増加により、予測期間中に最も高いCAGRで成長すると予想されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 閉経後骨粗鬆症治療市場：変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 閉経後骨粗鬆症治療市場：薬剤クラス別のビジネス分析

  • 市場シェア：薬剤クラス別 (2024年・2030年)
  • 薬剤クラス別ダッシュボード
  • 市場規模の予測と動向分析：薬剤クラス別 (2018～2030年)
  • ブランド
  • ジェネリック医薬品

第5章 閉経後骨粗鬆症治療市場：種類別のビジネス分析

  • 市場シェア：種類別 (2024年・2030年)
  • 種類別ダッシュボード
  • 市場規模の予測と動向分析：種類別 (2018～2030年)
  • ビスホスホネート
  • 副甲状腺ホルモン療法
  • カルシトニン
  • 選択的エストロゲン阻害剤モジュレーター（SERM）
  • ランクリガンド阻害剤
  • その他の製品

第6章 閉経後骨粗鬆症治療市場：流通チャネル別のビジネス分析

  • 市場シェア：流通チャネル別 (2024年・2030年)
  • 流通チャネル別ダッシュボード
  • 市場規模の予測と動向分析：流通チャネル別 (2018～2030年)
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 閉経後骨粗鬆症治療市場：地域別の推定・動向分析

  • 市場シェア分析：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 国別（2018～2030年）
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別（2018～2030年）
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別（2018～2030年）
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別（2018～2030年）
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別（2018～2030年）
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参加者概要
  • 企業の市場ポジション分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Cipla
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Postmenopausal Osteoporosis Treatment Market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 Global Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 6 Global Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Postmenopausal Osteoporosis Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Canada Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Mexico Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 Mexico Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Postmenopausal Osteoporosis Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Europe Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 UK Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 UK Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Germany Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 France Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 France Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Italy Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Spain Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Spain Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Norway Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Norway Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Norway Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Denmark Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Denmark Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Sweden Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 Sweden Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Postmenopausal Osteoporosis Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Japan Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Japan Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 China Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56 China Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 China Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 India Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 India Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 India Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Australia Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65 South Korea Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 66 South Korea Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Thailand Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 69 Thailand Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Postmenopausal Osteoporosis Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 Latin America Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 73 Latin America Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Brazil Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 76 Brazil Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Argentina Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Postmenopausal Osteoporosis Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85 South Africa Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91 UAE Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Postmenopausal Osteoporosis Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Postmenopausal Osteoporosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Postmenopausal Osteoporosis Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation Drug Class
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug Class, Type and Distribution Channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Postmenopausal Osteoporosis Treatment Market dynamics
  • Fig. 12 Postmenopausal Osteoporosis Treatment Market: Porter's five forces analysis
  • Fig. 13 Postmenopausal Osteoporosis Treatment Market: PESTLE analysis
  • Fig. 14 Postmenopausal Osteoporosis Treatment Market: Drug Class segment dashboard
  • Fig. 15 Postmenopausal Osteoporosis Treatment Market: Drug Class market share analysis, 2024 & 2030
  • Fig. 16 Branded market, 2018 - 2030 (USD Million)
  • Fig. 17 Generics market, 2018 - 2030 (USD Million)
  • Fig. 18 Postmenopausal Osteoporosis Treatment Market: Type segment dashboard
  • Fig. 19 Postmenopausal Osteoporosis Treatment Market: Type market share analysis, 2024 & 2030
  • Fig. 20 Bisphosphonates market, 2018 - 2030 (USD Million)
  • Fig. 21 Parathyroid Hormone Therapy market, 2018 - 2030 (USD Million)
  • Fig. 22 Calcitonin market, 2018 - 2030 (USD Million)
  • Fig. 23 Selective Estrogen Inhibitors Modulator (SERM) market, 2018 - 2030 (USD Million)
  • Fig. 24 Rank Ligand Inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 25 Other Products market, 2018 - 2030 (USD Million)
  • Fig. 26 Postmenopausal Osteoporosis Treatment Market: Distribution Channel segment dashboard
  • Fig. 27 Postmenopausal Osteoporosis Treatment Market: Distribution Channel market share analysis, 2024 & 2030
  • Fig. 28 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 31 Postmenopausal Osteoporosis Treatment Market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait Postmenopausal Osteoporosis Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework
目次
Product Code: GVR-4-68040-065-0

Postmenopausal Osteoporosis Treatment Market Growth & Trends:

The global postmenopausal osteoporosis treatment market size is expected to reach USD 13.7 billion by 2030 and is expected to expand at a CAGR of 4.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has grown significantly as a result of the growing geriatric population and lifestyle changes. As the older population is more susceptible, their population growth is anticipated to be a major driving force behind the market expansion. For instance, the number of people aged 60 years and above is predicted to rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050, according to the World Health Organization's October 2021 report. As a result, the market is anticipated to expand during the forecast period due to a rise in demand for postmenopausal osteoporosis treatment among older people.

In addition, lifestyle modifications like inactivity, excessive alcohol consumption, smoking, long work hours, and unhealthy eating patterns have an impact on menopause and increase the risk of osteoporosis in many women around the globe. Furthermore, age, smoking, alcohol consumption, and the use of drugs to address illnesses like gonadotropins, excessive thyroid hormone use, & cytotoxic agents are a few of the risk factors that can lead to low bone density and the development of the condition in women after menopause. Thus, it will drive the market growth. In 2021, more than 200 million women were affected with osteoporosis, and 1 in 3 women over 50 years of age are predicted to sustain an osteoporosis fracture, according to statistics from the International Menopause Society (IMS). As a result of the aforementioned factors, it is anticipated that the studied market will expand over the projected period.

However, it is anticipated that during the projection era, low awareness about the disease will impede industry growth. In the forecast period, there will likely be a significant increase in research and development efforts as a result of investments made by industry participants and research institutions. For instance, according to the information posted on clinicaltrial.gov, as of June 2021, there were approximately 25 ongoing phase III as well as phase IV clinical trials for osteoporosis medications in the U.S. Consequently, as a result of the aforementioned factors, the market is expected to grow over the forecast period. For instance, Eli Lilly and Company is creating blosozumab, a humanized IgG4 monoclonal antibody, to treat postmenopausal osteoporosis. It is an inhibitor of the SOST protein and is presently undergoing phase II clinical studies.

Postmenopausal Osteoporosis Treatment Market Report Highlights:

  • Branded osteoporosis drugs dominated the market, accounting for a share of 54.0% in 2024. These medications are widely used due to their proven effectiveness, regulatory approvals, and strong market presence.
  • Retail pharmacies dominated the market in 2024. The growing geriatric population and the increasing prevalence of osteoporosis have been key factors driving the demand for medications through this distribution channel.
  • North America held the largest share in 2024 due to the strong presence of key market participants, as well as rising R&D spending and federal assistance, in the region
  • Asia Pacific is expected to grow at the highest CAGR over the projected period due to the rising prevalence of target disease, the growing aging population, and the increasing adoption of postmenopausal osteoporosis treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Postmenopausal Osteoporosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Postmenopausal Osteoporosis Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Generics
    • 4.5.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Postmenopausal Osteoporosis Treatment Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Bisphosphonates
    • 5.4.1. Bisphosphonates Market, 2018 - 2030 (USD Million)
  • 5.5. Parathyroid Hormone Therapy
    • 5.5.1. Parathyroid Hormone Therapy Market, 2018 - 2030 (USD Million)
  • 5.6. Calcitonin
    • 5.6.1. Calcitonin Market, 2018 - 2030 (USD Million)
  • 5.7. Selective Estrogen Inhibitors Modulator (SERM)
    • 5.7.1. Selective Estrogen Inhibitors Modulator (SERM) Market, 2018 - 2030 (USD Million)
  • 5.8. Rank Ligand Inhibitors
    • 5.8.1. Rank Ligand Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.9. Other Products
    • 5.9.1. Other Products Market, 2018 - 2030 (USD Million)

Chapter 6. Postmenopausal Osteoporosis Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Postmenopausal Osteoporosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Eli Lilly and Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AbbVie Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Cipla
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives